论文部分内容阅读
The most important and successful antibody therapies of solid tumors cover the EGFR/Her-2/neu group.A real breakthrough in targeted cancer therapies could be reached by use of trastuzumab in Her-2/neu overexpressing breast cancer due to Her-2/neu gene amplifications.Since two years these therapies are known to be successful in a subset of gastric carcinomas too.